Dysphagia in Thoracic Surgical Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04487028 |
Recruitment Status :
Recruiting
First Posted : July 27, 2020
Last Update Posted : November 19, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Thoracic Diseases | Procedure: Fiberoptic Endoscopic Evaluation of Swallowing |
Study Type : | Observational |
Estimated Enrollment : | 240 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Dysphagia in Thoracic Surgical Patients: Incidence, Risk-factors, and Health Related Outcomes |
Actual Study Start Date : | August 25, 2020 |
Estimated Primary Completion Date : | January 2022 |
Estimated Study Completion Date : | August 2022 |

Group/Cohort | Intervention/treatment |
---|---|
Thoracic Surgical Patients
Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
|
Procedure: Fiberoptic Endoscopic Evaluation of Swallowing
This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
Other Name: FEES |
- Penetration Aspiration Scale [ Time Frame: Baseline ]This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
- Yale Residue Severity Rating Scale [ Time Frame: Baseline ]This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).
- Vocal Fold Mobility Impairment [ Time Frame: Baseline ]During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- adults aged 18 - 90 years old
- undergoing planned or emergent thoracic surgery via clamshell and/or extended thoracotomy
- confirmed negative COVID-19 test
- willing to participate in postoperative swallowing evaluation testing.
Exclusion Criteria:
- individuals under the age of 18.
- pregnant
- or those testing positive for COVID-19
- Additionally, the inability to demonstrate appropriate alertness and cognitive status following the procedure will exclude a participant from participating in this study to ensure protection of vulnerable individuals.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04487028
Contact: Amber R Anderson, MS | 352-237-8632 | amber.anderson@phhp.ufl.edu |
United States, Florida | |
Cardiovascular Clinic at UF Health UF | Recruiting |
Gainesville, Florida, United States, 32610 | |
Thoracic and Cardiovasscular Surgery at UF Health | Recruiting |
Gainesville, Florida, United States, 32610 | |
UF Health at the University of Florida | Recruiting |
Gainesville, Florida, United States, 32610 |
Principal Investigator: | Emily K Plowman, PhD | University of Florida |
Responsible Party: | University of Florida |
ClinicalTrials.gov Identifier: | NCT04487028 |
Other Study ID Numbers: |
IRB202000724-A |
First Posted: | July 27, 2020 Key Record Dates |
Last Update Posted: | November 19, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Dysphagia Extubation Vocal Fold Mobility Impairment Peak Cough Flow (PCF) |
Deglutition Disorders Thoracic Diseases Esophageal Diseases Gastrointestinal Diseases |
Digestive System Diseases Pharyngeal Diseases Otorhinolaryngologic Diseases Respiratory Tract Diseases |